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To determine the clinical profile and efficacy of accelerated
recombinant tissue-type plasminogen activator (rt-PA) dose regi-
mens, five different strategies of thrombolytic therapy in a total of
232 patients were systematically evaluated in the setting of acute
myocardial infarction. The fifth strategy involved a combination
of accelerated rt-PA and intravenous urokinase (regimen E). A
weight-adjusted dose of 1.25 mglkg body weight of tissue plas-
minogen activator over 90 min (regimen C) yielded the highest
coronary patency rate (83%)at acute angiography. The associated
in-hospital reocclusion rate for this regimen was low (4%). An
exaggerated (60-min) dosage regimen yielded an inferior coronary
patency rate (63%). Combination therapy (regimen E) was asso-
ciated with a 72% patency rate and 3% reocclusion rate.
Marginal improvement in global ejection fraction and regional
wall function was demonstrated with all strategies by predischarge
catheterization. Bleeding complications were most common at the
periaccess site and were not different from those in previous
experiences reported with conventional 3-h dosing regimens.
The major goal of myocardial reperfusion therapy is to
restore coronary blood flow as quickly as possible in the
highest number of patients. To date, most coronary angio-
graphic studies (1-5) 60 to 90 min after intravenous throm-
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Measurements of baseline, 30-min and 3-h levels of tissue
plasminogen activator, fibrinogen and fibrin(ogen) degradation
products were obtained. At 3 h, fibrinogen levels of <1 glliter
were demonstrated with combination therapy (regimen E) as well
as with regimen C. Major clinical outcomes including death,
reocclusion and reinfarction also showed a tendency to be less
common with regimen C.
Therefore, although accelerated dose regimens of rt-PA do not
reliably yield acute coronary patency rates >85%, an acute
coronary patency rate of approximately 85% can be approached.
However, exaggerated (60-min) accelerated therapy may be asso-
ciated with inferior coronary patency rates compared with con-
ventional regimens.
The profile of heightened velocity of reperfusion, low reocclu-
sion rates and a bleeding complication frequency comparable with
that with conventional thrombolytic regimens suggests that accel-
erated rt-PA therapy deserves more extensive investigation.
(J Am Coli CardioI1992;19:482-9)
bolytic therapy have demonstrated a patency success rate
:5.75%. Furthermore, the time to achieve thrombolysis has
averaged ~45 min in patients with successful early therapy
(6). Recently, however, new accelerated dosing regimens
with intravenous recombinant tissue-type plasminogen acti-
vator (rt-PA) have achieved coronary thrombolysis more
rapidly in ~85% of patients (7-10). Experimental studies (11)
have indicated that clot lysis may be proportional to drug
levels, leading to the supposition that achieving higher levels
early in treatment could both speed the rate and enhance the
likelihood of reperfusion.
We undertook a new clinical trial to systematically exam-
ine whether these "front-loaded" regimens (12) of rt-PA
could be further improved by exaggerating the accelerated
aspect of dosing. trying weight-adjusted dosing or replicating
the promising results of other alternative regimens. Conven-
tional dosing with 100 mg over 3 h was not employed
because of our previous extensive data base documenting
expected patency rates. Our preliminary hypothesis was that
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of a 20-mg intravenous bolus injection of rt-PA, followed by
a 30-min wait, with 80 mg subsequently administered intra-
venously over the next 2 h. Finally, regimen E consisted of
combination therapy with 1mg/kg of intravenous rt-PA over
30 min given simultaneously with 1.5 million U of urokinase
over 1 h. This strategy was similar to that used in the
Thrombolysis and Angioplasty in Myocardial Infarction
(TAMI)-5 Study (4), except that front-loaded rt-PA was
employed. In regimens A to C, no more than a maximum of
120 mg of tissue rt-PA was used. In regimen D, a total of
100 mg was given and in regimen E, a maximal dose of 90 mg
was given.
Cardiac catheterization. All patients underwent emer-
gency cardiac catheterization, including coronary angiogra-
phy and left ventriculography, and delayed catheterization 5
to 10 days after the administration of thrombolytic therapy.
Infarct-related artery patency, the primary end point of the
study, was evaluated ~90 min after the initiation of throm-
bolytic therapy. The infarct-related artery was identified as
patent if Thrombolysis in Myocardial Infarction (TIM!)
grade 2 or 3 flow was present at the time of the fourth
diagnostic injection. An infarct-related vessel with TIMI
grade 0 or 1flow was defined as occluded. Left ventriculog-
raphy was performed at the time of immediate catheteriza-
tion and at the time of delayed catheterization 5 to 10 days
later in the standard right anterior oblique projection.
All cineangiograms were evaluated independently at the
core angiographic laboratory at the University of Michigan.
Qualitative analysis included TIMI perfusion grade (5) and
visual percent stenosis of the infarct-related vessel. This
analysis was performed by a cardiologist and technician who
had no knowledge of patient outcome. Global left ventricular
function was determined by the area-length method and
expressed as global ejection fraction (13). Regional wall
motion of the infarct and noninfarct zones was quantitatively
evaluated and expressed as standard deviations/chord by
means of the centerline chord method (14). Technically
inadequate studies due to lack of adequate contrast or
frequent ventricular extrasystoles were not included in the
analysis.
rt-PA =recombinant tissue-type plasminogen activator.
Table 1. Dosing Regimensaccelerated infusion of intravenous rt-PA would achieve an
acute coronary patency rate >85%. In addition, we were
interested in observing associated reocclusion rates with
accelerated therapy because few data exist concerning this
potential complication at the time of trial initiation (7).
Methods
Patient enrollment. The trial was conducted at six re-
gional cardiac referral centers in collaboration with 21 com-
munity hospitals (see Appendix). The protocol was ap-
proved by the Institutional Review Board at all participating
sites. Patients were identified and prospectively enrolled in
the emergency room setting.
Inclusion criteria included: age > 18 and <76 years;
ability to give informed consent for participation in the
study; symptoms consistent with acute myocardial infarc-
tion of >30-min duration unresponsive to standard sublin-
gual nitroglycerin therapy; ~1-mV ST segment elevation in
at least two of three inferior leads, two of six precordial
leads, leads I and aVL; ST segment depression in precordial
leads V1 through V4 consistent with posterior injury and
onset of ischemic symptoms :56 h from the time of throm-
bolytic therapy administration.
Exclusion criteria included: history of any significant
bleeding diathesis or known bleeding disorder; history of
gastrointestinal or genitourinary bleeding within the preced-
ing 4 weeks; history of any previous stroke or transient
ischemic attack; major surgery or organ biopsy within the
previous 14 days; uncontrolled hypertension defined by several
measurements as diastolic blood pressure > 110 mm Hg or
systolic blood pressure> 180 mm Hg after treatment for pain;
other serious advanced illnesses likely to limit the life expect-
ancy in the next several years; prolonged cardiopulmonary
resuscitation (> 10 min duration) within the previous 2 weeks;
severe trauma within the past 6 months that might predispose
the patient to intracranial, intrathoracic, intraabdominal or
retroperitoneal bleeding; psychologic or physical inability to
participate; women of child-bearing potential; prior coronary
artery bypass graft surgery and prior Q wave infarction in the
same electrocardiographic distribution as the current infarc-
tion.
Thrombolytic regimens (Table 1). Five thrombolytic drug
regimens (regimens A to E) were systematically evaluated.
Regimen A, designed to administer a high dose of rt-PA in an
accelerated manner, employed a dosage of 1 mg/kg over
30 min intravenously (10% as a bolus injection), followed by
0.25 mg/kg over the next 30 min. To evaluate the importance
of a front-loaded regimen at the same total dosage,
1.25 mg/kg of intravenous rt-PA was infused continuously
over 90 min in regimen B; the first 20 mg was given as an
intravenous bolus injection. Regimen C, similar to the pro-
tocol of Neuhaus et al. (7) but weight-adjusted, used
0.75 mg/kg over 30 min intravenously (10% as a bolus
injection) and 0.5 mg/kg over the subsequent hour. Regimen
D, identical to the protocol of McKendall et al. (8), consisted
Regimen
A
B
C
D
E
rt-PA Dosage
I mg/kg over 30 min (10% bolus);
0.25 mg/kg over 30 min
1.25 mg/kg over 90 min (20-mg bolus)
0.75 mg/kg over 30 min (10% bolus);
0.50 mg/kg over 60 min
20-mg bolus; 30-min wait; 80 mg over
120 min
I mg/kg over 30 min + urokinase (1.5
million U) over I h
Maximal
rt-PA
Dose (mg)
120
120
120
100
90
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Table 2. Baseline Characteristics of 219 Patients
*Median. tCardiovascular risk factors previously defined. CV = cardio-
vascular; MI = myocardial infarction; PVD = peripheral vascular disease.
Regimens A to E are defined in Table I.
Regimen
A B C D E
37 33 61 46 42
59 58 60 55 58
78 79 72 78 81
165 185 151 148 183
118 168 144 156 136
44 39 34 49 43
56 61 64 51 57
0 0 2 0 0
41 39 46 37 38
24 12 31 37 24
14 12 15 30 19
70 64 64 65 60
3 0 3 4 2
0 6 5 9 0
68 58 59 63 48
II 3 12 7 10
Center at the Duke Databank for Cardiovascular Disease.
The data were verified independently by study monitors
through review of the clinical records. The Data and Safety
Monitoring Board met regularly during the study to review
the clinical outcome of each patient. After approximately 25
patients were treated with each regimen, the board recom-
mended treating additional patients with the ongoing regi-
men or proceeding to the next dosage regimen. Specifically,
if the upper 95% confidence limit for acute coronary patency
did not exceed 85%, as defined by our primary hypothesis,
the next regimen was initiated.
No.
Age (yr)*
(%male)
Time to treatment (min)*
Treatment until final
angiographic injection
(min)*
Infarct location (%)
Anterior
Inferior
Unknown
CV risk factors (%)t
Hypertension
Hypercholesterolemia
Diabetes mellitus
Tobacco use
Prior stroke
PVD
Family history
Prior MI
Results
Patient characteristics (Table 2). A total of 232 patients
were enrolled in the study; 219 were included in the final
analysis. Three patients received no thrombolytic therapy
and nine were misdiagnosed as having acute myocardial
infarction. Of these nine, two had acute pericarditis, six had
coronary artery disease but normal cardiac enzyme levels
and one had normal coronary arteries by catheterization and
did not "rule in" by enzyme analysis. One additional patient
was inadvertently treated with a thrombolytic regimen dif-
ferent from that specified by the protocol.
The number of patients treated in each group and their
baseline clinical and angiographic characteristics are listed in
Table 2. There were no substantial differences in baseline
characteristics.
Patency and reocclusion rates (Table 3). Infarct-related
artery patency, the number of patients treated in each
In-hospital care. After emergency catheterization, pa-
tients were transferred to the coronary care unit where they
received standard care, including lidocaine, oxygen, mor-
phine as needed for pain and nitrates either topically or
intravenously. Aspirin (325 mg/day) was given immediately
on entry into the study in the emergency room. Acontinuous
infusion of intravenous heparin was also begun at 1,000 Ulh
at the end of thrombolytic therapy administration. The
patients continued to receive intravenous heparin until the
time of repeat catheterization 5 to 10 days later and efforts
were made to sustain the activated partial thromboplastin
time at two times the control value for our laboratory.
Intravenous beta-adrenergic blockade was used with meto-
prolol (15 mg over three divided doses) unless the patient
was hypotensive, in cardiogenic shock, had severe chronic
obstructive pulmonary disease or had second or third degree
atrioventricular block. Patients were also treated with a
calcium channel antagonist at the discretion of the clinician;
no other antiplatelet agents such as dipyridamole were used
routinely.
Hemorrhagic measurements. Bleeding observed during
the hospital stay was defined as follows: mild if it was of no
clinical consequence, did not require transfusion or resulted
in a total blood loss of <250 ml; moderate if 250 to 500 ml of
observed blood loss was noted; severe if any of the following
events occurred: >500 ml of blood loss necessitating a
transfusion, intracranial bleeding, gastrointestinal or other
external or internal bleeding causing hypotension and requir-
ing emergency transfusion. The site of bleeding, baseline and
nadir hematocrit as well as transfused units of packed red
blood cells were recorded for all patients. However, trans-
fusion was withheld in hemodynamically stable patients
unless the hematocrit was documented as <22%. In the
setting of hemodynamic instability unresponsive to crystal-
loid infusion and with clinical evidence of significant blood
loss, transfusions were given.
Coagulation tests. Blood samples were collected on 0.01
molar citrate and 200 kIU/ml aprotinin at baseline, 30 min
and 3 h after initiation of thrombolytic therapy and were
immediately processed and kept frozen at -20°C until as-
sayed at the coagulation laboratory. Fibrinogen was deter-
mined by a coagulation rate assay. Fibrin(ogen) degradation
products were analyzed by the tanned red cell agglutination
inhibition technique at the core hematology laboratory at the
University of Vermont. These techniques have been previ-
ously described (15).
Statistical methods. Continuous baseline and outcome
variables were summarized using the median and interquar-
tile range (25th and 75th percentiles) and discrete variables
are expressed as percent; 95% confidence intervals are
calculated for major clinical outcomes. Because of the
exploratory nature of the study. no statistical comparisons
were performed.
Case report forms were completed by the clinical re-
search nurse coordinators and reviewed by the principal
investigators before submission to the Data Coordinator
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*Angiogram at 2:90 min. CI = confidence interval; rt-PA = recombinant
tissue plasminogen activator; TAMI = Thrombolysis and Angioplasty in
Myocardial Infarction Study Group. Regimens A to E are defined in
Table 1.
regimen and the respective confidence intervals are shown in
Table 3. Regimen C achieved a 90-min patency rate of 83%,
which was the highest rate observed for all five dosage
strategies. The lowest patency rate, 64%, occurred with
regimen B.
The proportion of patients with angiographically docu-
mented reocclusion in the five treatment regimens is also
shown in Table 3. Regimens D and A demonstrated the
highest rate of reocclusion at 14% and 11%, respectively; the
other regimens had a low reocclusion rate of 3% to 4%.
Baseline and follow-up left ventricular function (Table 4).
Although regimens A and E were associated with the most
improvement in both global and regional wall function,
predischarge left ventricular function was not significantly
different for any of the five treatments.
Bleeding complications (Table 5). The median change in
hematocrit was not different among the five treatment
groups. Although most bleeding complications involved the
periaccess site, no clinically significant difference in moder-
ate to severe bleeding was demonstrated among the different
regimens. No intracranial bleeding episodes were noted in
regimens A to D. However, with regimen E, there were two
intracranial bleeding events. The first patient who experi-
Table 3. Infarct-Related Vessel Patency and Reocclusion*
Regimen
A
B
C
D
E
Previous TAMI
experience (rt-PA
monotherapy)
Patency
(%) 95% CI
63 47-79
61 44-77
83 74-93
67 53-81
72 58-86
77 78-80
Reocclusion
(%)
11
3
4
14
3
13.6
95% CI
0-23
0-10
0-9
3-26
0-8
10.8-16.4
Table S. Hemorrhagic Measurements
Regimen
A B C D E
Decrease in hematocrit*
All patients 11 10 13 14 13
Nonsurgical 11 10 10 13 13
2:2 units transfused (%)
All patients 27 12 31 22 36
Nonsurgical 13 7 14 11 16
Bleeding sites (%)t
Periaccess 16 6 7 15 10
Gastrointestinal 3 6 2 7 2
Genitourinary 0 9 0 0 7
Retroperitoneal 3 3 0 0 0
Intracranial 0 0 0 0 5
*Admission minus nadir median hematocrit; tmoderate or severe bleed-
ing. Regimens A to E are defined in Table 1.
enced an intracranial bleeding episode had a history of
hypertension for 15 years and remained hypertensive despite
treatment with vasodilators. He developed receptive aphasia
and total right-sided hemiparesis. The second patient with an
intracranial bleeding event had a history of both hyperten-
sion and heavy alcohol consumption. He developed a left
thalamic hemorrhage and, despite placement of a ventricu-
lostomy tube, his neurologic status continued to deteriorate
and he died 6 days after presentation.
Hematologic findings (Table 6). Baseline, 30-min and 3-h
postinfusion levels for rt-PA, fibrinogen and fibrin(ogen)
degradation products are shown in Table 6. As expected,
rt-PA levels were the highest in regimens A and E 30 min
after starting the infusion. Levels were much lower at both
30 min and 3 h in regimen D, consistent with the delay
between the bolus injection and subsequent infusion. Fibrin-
ogen levels at 3h were considerably lower in regimens Cand
E than with the other strategies. Combination therapy with
urokinase in regimen E was associated with a much higher
level of fibrin(ogen) degradation products.
Table 4. Left Ventricular Function
Regimen
A (n = 37) B (n = 33) C (n = 61) D (n = 46) E (n = 42)
Global ejection fraction (%)
Acute 35/46/57 46/56/59 43/53/58 42/51/56 41/48/57
Follow-up 48/56/64 48/57/64 47/53/60 39/51/57 44/54/61
Infarct zone regional wall
motion (SD/chord)*
Acute - 3.5/-2.9/-2.2 - 3.2/-2.8/-2.3 -3.6/-3.0/-2.4 -3.4/-2.9/-2.0 -3.5/-3.0/-2.3
Follow-up -2.9/-2.0/-0.6 -3.2/-2.7/-1.0 -3.1/-2.6/-1.1 -3.2/-2.7/-1.9 -2.9/-2.4/-1.3
Noninfarct zone regional
wall motion (SD/chord)*
Acute -1.4/-0.2/-0.6 -1.7/0.1/0.9 -1.0/0.1/0.9 -1.7/-1.0/0.6 -2.1/-1.0/0.2
Follow-up -1.0/-0.3/0.7 -0.8/-0.1/0.6 -1.4/-0.3/0.6 -1.2/-0.5/0.5 -1.9/-0.5/1.3
* Data are shown as median (25th/50th/75th percentile). Regimens A to E are defined in Table I.
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Table 6. Hematologic Measurements
Regimen
A B C D E
(n =37) (n =33) (n =61) (n =46) (n =42)
rt-PA antigen (ng/ml)*
Baseline 12/16/21 10/12/18 12/17/26 14/19/27 12/16121
30 min 1,108/3,450/4,800 920/1,390/2,300 888/2,005/3,100 129/240/500 998/3,550/5,250
3h 34/53/73 36/47/72 48/59/95 83/183/445 37/53/113
Fibrinogen (g/liter)*
Baseline 2.3/2.6/3.6 2.1/2.4/2.8 2.2/2.8/3.6 2.2/2.4/3.2 2.2/2.6/3.3
30 min 0.3/1.3/2.2 0.5/2.2/2.5 0.5/2.0/2.6 2.0/2.2/2.8 0.1/0.8/1.7
3h 0.1/1.1/1.7 0.2/1.3/1.8 0.2/0.8/1.6 0.8/1 .3/1.8 0.1/0.4/1.3
FDP(~ml)*
Baseline 10/10/12 717110 717111 71718 8/8/17
30 min 40/640/2,000 7/12/1,125 11/56/1 ,800 717116 102/900/2,200
3h 40/400/2,200 18/103/1,510 104/340/1 ,400 34/110/245 129/1 ,450/2,200
*Data are shown as median (25th/50th/75th percentile). FDP =fibrin(ogen) degradation products; rt-PA = recombinant tissue type plasminogen activator.
Regimens A to E are defined in Table I.
Major clinical outcomes with the dift'erent drug regimens
(Table 7). Death, reocclusion, restenosis and reinfarction
tended to be less frequent in regimen C. There was no
significant difference in the incidence of recurrent ischemia
or congestive heart failure among the different treatment
strategies.
Discussion
This study demonstrates some of the limitations and
potential advantages of accelerated rt-PA. First, accelerated
weight-adjusted dose regimens were not associated with
acute coronary patency rates >85%. In fact, a more accel-
erated dosage strategy over 60 min yielded the lowest
patency rate of any regimen in the study. Despite rapid
dosing and high early patency rates, the reocclusion rate of
the infarct-related artery was not increased compared with
previous studies of 3-h regimens. Finally, bleeding compli-
cations appear to be similar to those in previous reports with
conventional infusion.
Patency rates. Regimens A, Band D produced early
patency rates at immediate catheterization that were not
Table 7. Major Clinical Outcomes
compatible with the potential for >85% patency as demon-
strated by the 95% confidence intervals. For regimen A, the
limited patency rate may have been a consequence of
accelerated clearance of the drug with the exaggerated
60-min front-loaded infusion (16). Regimen B, which yielded
the lowest observed patency rate, perhaps emphasizes the
need for the 30-min front-loaded infusion to improve the
velocity and hence the effectiveness of accelerated adminis-
tration. The patency rate in regimen D of only 67% is
substantially lower than that previously reported (8). This
discrepancy may be due to sampling error because only 46
patients were evaluated. In addition, our final diagnostic
injection at immediate catheterization occurred at a median
time of 148 min and not 90 min. A high early patency rate
followed by early reocclusion would not have been detected
by these angiograms. Regimen C, a weight-adjusted regimen
similar to that evaluated by Neuhaus et al. (7), yielded our
best observed patency rate of 83%. Although the upper
confidence limit for this particular strategy reached 93%, the
interval for this point estimate was somewhat wide at 74% to
93%. Finally, with combination front-loaded rt-PA and
urokinase in regimen E, a 72% patency rate was demon-
Regimen
A B C D E
(n =37) (n =33) (n =61) (n =46) (n =42)
(%) (%) (%) (%) (%)
Death II 6 2 7 14
Reocclusion II 3 4 14 3
Restenosis 5 9 0 2 0
Recurrent ischemia 35 18 30 20 17
Reinfarction 8 6 3 2 5
Congestive heart failure 24 27 30 35 26
Total stroke 3 3 0 2 5
Regimens A to E are defined in Table I.
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Table 8. Velocity of Reperfusion in Reported Studies
Angiography Patency
60 min 90 min
No. (%) (%)
TAMI-7 (regimen C) 61 Not done 83
(present study)
Neuhaus et al. (7) 74 74 91
RAAMI (9)
Accelerated dosing 143 76 82
Conventional dosing 138 62 75
TAPS (10)
RAAMI = Rapid Administration of Alteplase in Myocardial Infarction;
TAMI = Thrombolysis and Angioplasty in Myocardial Infarction Study:
TAPS = Tissue Plasminogen Activator Versus Anistreplase Patency Study.
Regimen C is defined in Table 1.
strated, which is similar to that reported with previous
combination dosage schemes (2,4,17).
The 83% patency rate achieved in regimen C fell short of
the initial report of 90-min patency with accelerated therapy
(7). Even though our dose was weight-adjusted, the total
amount of rt-PA administered over time was similar. How-
ever, our patency rate was almost identical to that observed
by Carney et a1. (9) using the protocol of Neuhaus et a1. (7).
This study reported a 90-min angiographically documented
patency rate of 82% in 143 patients. In the recently com-
pleted Tissue Plasminogen Activator versus Anistreplase
Patency Study (10), the same accelerated regimen yielded an
84.6% 90-min patency rate in 195 patients. The patency rate
with this front-loaded strategy was higher than that achieved
with 30 U of anistreplase and was associated with a lower
28-day mortality rate. A heightened velocity of coronary
patency was also demonstrated in all three studies (7,9,10) as
documented by 60-min angiography when compared with
conventional regimens (Table 8). The 6O-min patency rate of
74% to 76% compares favorably with the 45% to 60%
patency rate observed with conventional regimens (6).
Reocclusion rates, There was concern that any regimen
with a higher early patency rate might be associated with a
greater propensity for reocclusion (18). However, a surpris-
ing finding with rt-PA regimens is th~ low reocclusion rate.
The reocclusion rate of 4% with regimen C is much lower
than the 13% rate seen in our previous studies (1-3,19)
evaluating rt-PA as monotherapy. This finding is consider-
ably lower than the 11% rate of reocclusion reported by
Neuhaus et a1. (7) as well as others (10) and compares
favorably with that reported with urokinase monotherapy
(6%) (20). The low reocclusion rate of 3% with combination
therapy in regimen E is similar to previously reported rates
from our study group (2,4). Although reocclusion of the
infarct-related vessel has been reported (21,22) as being
exceptionally low with prolonged maintenance infusions of
rt·PA, the same has not held true for the conventional 3-h
regimen (6,23).
Ventricular function. Global ejection fraction and re-
gional wall function showed a marginal improvement with all
treatment strategies. Although the improvement from base-
line to predischarge left ventricular function was greatest for
regimens A and E, this finding most likely reflects worse
baseline left ventricular function at the time of acute cathe-
terization. Previous studies (24,25) have shown that the most
important predictor of improved systolic function is de-
pressed baseline function. These findings are comparable to
those in studies evaluating conventional dosing.
Bleeding complications. Overall, bleeding complications
were not substantially different from those previously re-
ported (1-6,23,26-28) in patients treated with conventional
regimens of rt·PA. Most significant bleeding episodes oc-
curred at the periaccess site. There were, however, two
intracranial bleeding events in regimen E with combination
therapy. Both patients had a predisposition for this compli-
cation. Furthermore, the incidence of intracranial bleeding
in previous studies evaluating combination therapy has been
low (4,17). Thus far, studies (7,9,10) evaluating front-loaded
rt-PA monotherapy have been associated with a low (0.3%)
intracranial bleeding rate, which is similar to or lower than
the rate with conventional 3-h infusions.
Plasminogen activator and fibrinogen levels. This study
demonstrates that high levels of rt-PA can be achieved
within 30 min with accelerated therapy. The profound de-
crease in rt-PA levels by 3 h further emphasizes its short
half-life and rapid clearance from the bloodstream. This
finding perhaps reinforces the need for adequate anticoagu-
lation once a fibrin-specific agent is administered to prevent
reocclusion (29-31).
A significant decrease in fibrinogen levels to <1 g/liter
was seen in regimens Cand E, representing a more profound
decrease than that documented by previous studies (27,28,
32,33). This may reflect less relative fibrin selectivity at high
systemic drug levels. In addition, these two strategies pro-
duced a more sustained systemic fibrinolytic effect with
higher levels of fibrin(ogen) degradation products docu-
mented at 3 h of infusion. As demonstrated with previous
combination therapies (2,4,17), the most profound increase
was in regimen E with the addition of urokinase. Overall,
these hematologic variables demonstrate that a substantial
fibrinogenolytic effect can be achieved with front-loaded
therapy. This perhaps correlates with the low reocclusion
rate seen particularly in regimens C and E.
Clinical outcome. Although the number of patients
treated in each group was small, the trend toward a more
favorable clinical outcome in regimen C is of interest. The
lower rate of death, reocclusion, reinfarction and intracra-
nial bleeding is encouraging. However, recurrent ischemia
as demonstrated with conventional rt-PA therapy remains a
significant limitation of reperfusion therapy. This finding
further emphasizes the need for the development of adjunc-
tive therapies with fibrinolytic therapy to decrease the inci-
dence of this adverse clinical outcome (19,34).
Limitations. Limitations of this study should be noted.
The first is that this pilot study was open labeled and not
randomized. Therefore, significant bias could exist in base-
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line characteristics among the groups. However, previous
studies have not identified major clinical factors that have an
impact on the likelihood of reperfusion. Second, confidence
intervals for patency and reocclusion rates for each drug
strategy were wide because of the small sample size.
Conclusions. Accelerated dose regimens of intravenous
rt-PA do not reliably yield early (90-min) coronary patency
rates >85%. However, an early coronary patency rate of
approximately 85% can be approached. An accelerated
rt-PA dose regimen, in which the drug is given too rapidly or
without a significant front-loaded 30-min infusion, may be
associated with lower coronary patency rates, probably
reflecting saturation of plasminogen receptors (34). In-
hospital reocclusion rates appear to be low compared with
those seen with conventional therapy. To date, bleeding
complications are comparable to those previously reported.
These findings suggest that further study is warranted to
determine whether the heightened velocity and ceiling of this
reperfusion method are associated with a better clinical
outcome. Aweight-adjusted front-loaded regimen ofrt-PA is
currently being investigated in an ongoing large international
multicenter trial.
We sincerely appreciate the technical assistance of Cynthia Gardner in the
preparation of the manuscript.
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